Pharma BD Deal Intelligence
AstraZeneca's $175M-upfront, up-to-$4.4B Harbour BioMed antibody alliance kept expanding—into oncology ADCs and T cell engagers by November 2025—while doubling as a defiant $105M equity stake in China amid geopolitical pressure.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca today announced an expanded global strategic collaboration with Harbour BioMed to accelerate the discovery and development of next-generation…
AstraZeneca details $2.5B investment in China's political center, funding R&D center, biotech pacts. The article references the simultaneous Harbour BioMed…
Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth. The release frames the AstraZeneca…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
AstraZeneca and Harbour BioMed entered a global strategic collaboration (announced March 21, 2025) with $175M in upfront/near-term payments and option fees plus up to $4.4B in development and commercial milestones, tiered royalties, and a $105M equity investment by AstraZeneca for 9.15% of newly issued Harbour BioMed shares. AstraZeneca holds an option to license preclinical programs generated on Harbour's Harbour Mice platform and nominates further targets for next-generation multi-specific antibody discovery. Harbour BioMed's H1 2025 interim results confirm AstraZeneca completed the 9.15% equity investment and the collaboration is in force. On November 23, 2025 the companies advanced the collaboration into next-generation oncology biotherapeutics, including antibody-drug conjugates (ADCs) and T cell engagers, with AstraZeneca to nominate discovery programs annually over four years; the expansion's economics are consistent with the original March 2025 framework (no new dollar figures disclosed).
52M US cases/yr · $300.0B Global Immunology + Oncology Market (2024) · 9.15% AZ Equity Stake in Harbour BioMed
The AstraZeneca-Harbour BioMed collaboration targets therapeutic antibody discovery across immunology, oncology, and additional disease areas rather than a single indication. Immunology encompasses autoimmune (rheumatoid arthritis, lupus, IBD, psoriasis), allergic (atopic dermatitis, asthma), and chronic inflammatory disorders, collectively affecting over 50 million Americans. Oncology represents the largest therapeutic category globally, with over 2 million new US cancer diagnoses annually. Multi-specific antibody formats including bispecifics, trispecifics, and T-cell engagers have emerged as a critical modality for engaging complex biology that monospecific antibodies cannot address. Approved bispecifics include blinatumomab (Blincyto, Amgen, CD19xCD3), teclistamab (Tecvayli, J&J, BCMAxCD3), talquetamab (Talvey, J&J, GPRC5DxCD3), mosunetuzumab (Lunsumio, Roche, CD20xCD3), glofitamab (Columvi, Roche), epcoritamab (Epkinly, AbbVie/Genmab), elranatamab (Elrexfio, Pfizer), amivantamab (Rybrevant, J&J, EGFRxMET), tarlatamab (Imdelltra, Amgen, DLL3xCD3), and faricimab (Vabysmo, Roche, Ang2xVEGF). Harbour's fully human heavy-chain-only antibody platform (Harbour Mice) enables streamlined bispecific engineering.
The multi-specific antibody competitive landscape is fragmented by platform technology and indication. In CD3-based T-cell engagers for heme malignancy and solid tumors: Blincyto (blinatumomab, Amgen), Tecvayli (teclistamab, J&J), Talvey (talquetamab, J&J), Lunsumio (mosunetuzumab, Roche), Columvi (glofitamab, Roche), Epkinly (epcoritamab, AbbVie/Genmab), Elrexfio (elranatamab, Pfizer), Imdelltra (tarlatamab, Amgen). EGFRxMET: Rybrevant (amivantamab, J&J). HER2 bispecifics: Zanidatamab (Ziihera, Jazz/BeiGene). Immunology bispecifics: faricimab (Vabysmo, Roche, Ang2xVEGF), bimekizumab (Bimzelx, UCB, IL17A/F), nemolizumab (Roche/Galderma). Competing discovery platforms include Genmab's DuoBody, Roche/Chugai's CrossMab, Regeneron's Veloci-Bi, Zymeworks' Azymetric, Merus Biclonics, Adimab, and Xencor's XmAb. Harbour's HCAb platform shares the heavy-chain-only approach with Teneobio (acquired by Amgen) and Biotheus.
On November 23, 2025 Harbour BioMed and AstraZeneca advanced their March 2025 global strategic collaboration into next-generation oncology biotherapeutics, including antibody-drug conjugates (ADCs) and T cell engagers. AstraZeneca will nominate discovery programs annually over four years; economics are consistent with the original framework (no new dollar figures disclosed).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Harbour BioMed (Nottingham) Ltd. (this deal) | 2025 | $4.6B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2025 deals · AstraZeneca PLC deals · Immunology deals